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Abstract
Background: This study evaluated the safety and efficacy of teduglutide in pediatric patients with short bowel syndrome–associated
intestinal failure (SBS-IF). Methods: A 24-week, phase III trial with 2 randomized, double-blind teduglutide dose groups and a
nonblinded standard of care (SOC) arm was used; patients received 0.025 mg/kg or 0.05 mg/kg teduglutide once daily. Safety end
points included treatment-emergent adverse events (TEAEs) and growth parameters. The primary efficacy/pharmacodynamic end
point was the number of patients who achieved a 20% reduction in parenteral support (PS) from baseline at week 24. Results:All
59 enrolled patients completed the study (0.025 mg/kg, n= 24; 0.05 mg/kg, n= 26; SOC, n= 9). Baseline demographics and disease
characteristics were comparable among groups. TEAEs were reported by 98% and 100% of patients in the teduglutide and SOC
groups, respectively. Themost commonTEAEs in the teduglutide-treated groups were pyrexia and vomiting. The primary end point
was achieved by 13 (54.2%), 18 (69.2%), and 1 (11.1%) patients who received 0.025 mg/kg teduglutide, 0.05 mg/kg teduglutide, and
SOC, respectively (P< 0.05 vs SOC). Both 0.025-mg/kg and 0.05-mg/kg teduglutide groups showed clinically significant reductions
in PS volume (P < 0.05 vs SOC), PS calories, days per week and hours per day of PS infusions, and increases in enteral nutrition
and plasma citrulline at week 24 compared with baseline. Two (8.3%, 0.025 mg/kg teduglutide) and 3 patients (11.5%, 0.05 mg/kg
teduglutide) achieved enteral autonomy. Conclusion: The safety profile of teduglutide was similar to that reported previously in
children and adults. Treatment with teduglutide was associated with significant reductions in PS for pediatric patients with SBS-IF
over 24 weeks. (JPEN J Parenter Enteral Nutr. 2020;44:621–631)
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Clinical Relevancy Statement
Parenteral support (PS)–dependent children with short
bowel syndrome–associated intestinal failure (SBS-IF) have
a high disease burden. In this 24-week, phase III study
of 2 randomized, double-blind teduglutide dose groups
and a nonblinded standard of care group, treatment with
teduglutide reduced PS volume, calories, and infusion time
in pediatric patients with SBS-IF. The safety profile was
consistent with previous experience in adults and children
with SBS-IF. In conjunction with expert management by
intestinal rehabilitation specialists in this study, daily tedug-
lutide injection was well tolerated and promoted intestinal
adaptation, as evidenced by reductions of PS requirements
in children with SBS-IF.
Introduction
Short bowel syndrome (SBS) is the most common cause of
intestinal failure (IF), defined as gut function inadequate
for satisfactory absorption of macronutrients, water, or elec-
trolytes to maintain growth and development.1 Long-term
administration of parenteral support (PS; parenteral nutri-
tion and/or intravenous fluids) is life-saving but associated
with potentially life-threatening complications, including
IF-associated liver disease, central line–associated blood
stream infections, and central venous thrombosis.1-3 En-
hancing intestinal adaptation minimizes dependence on PS,
thereby reducing the risk of complications4-6 and potentially
improving quality of life.7,8
Glucagon-like peptide-2 (GLP-2), a hormone secreted
by enteroendocrine L cells in the distal ileum and proximal
colon in response to the presence of unabsorbed luminal
nutrients,9,10 is a key component of the adaptive response
to intestinal malabsorption.9-12 Teduglutide, a recombinant
human GLP-2 analogue, is approved in the United States
and Europe for the treatment of patients 1 year of age
with SBS-IF at a dose of 0.05 mg/kg administered subcu-
taneously once daily.13,14 Teduglutide enables PS reductions
in heterogeneous populations of adult and pediatric patients
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with SBS-IF.5,15-19 A previous 12-week, open-label trial in
pediatric patients with SBS-IF (NCT01952080; EudraCT:
2013-004588-30) evaluated the safety of 3 different doses
and showed reduced PS requirements among patients re-
ceiving 0.025 and 0.05 mg/kg teduglutide.5 This manuscript
reports results from a subsequent 24-week study that further
evaluated the safety and efficacy of 0.025 and 0.05 mg/kg
teduglutide in children with SBS who were dependent
on PS.
Methods
A 24-week, phase III trial composed of 2 teduglutide
dose groups and 1 standard of care (SOC) arm enrolled
teduglutide-naı̈ve patients at 24 centers in North America
and Europe from June 2016 to August 2017 (Clinical-
Trials.gov, NCT02682381, EudraCT 2015-002252-27). The
study was conducted in accordance with the International
Council for Harmonisation of Technical Requirements
for Pharmaceuticals for Human Use, Good Clinical Prac-
tice, and the World Medical Association Declaration of
Helsinki. Upon approval from institutional review boards
or independent ethics committees, centers obtained written
informed consent from parents for study participation of
children and adolescents from 1 to 17 years of age re-
quiring PS for SBS. Inclusion and exclusion criteria were
similar to those of the previous 12-week study.5 Patients
considered incapable of advancing enteral nutrition (EN)
were excluded. A minimum enrollment of 28 patients (10
into each teduglutide dose group and 8 into the SOC arm)
was planned.During theminimum2-week screening period,
families chose to enroll the patient in either the teduglutide
or SOC treatment arm. Patients in the teduglutide treatment
arm were randomized 1:1 into 2 parallel-dose groups to
receive a once-daily subcutaneous injection of 0.025 mg/kg
or 0.05 mg/kg teduglutide according to a randomization
scheme generated by the sponsor, with a block size of 4
within an age group stratum. The volume of teduglutide ad-
ministered per kilogram was identical for both groups, and
investigators were blinded to the teduglutide concentration
received by patients.
All patients followed the same study visit schedule
(Figure 1). During the study period, PS and specialized
EN were recorded in intake diaries by the child’s parent
or guardian. At all site visits and during telephone con-
tacts, safety was monitored and PS requirements reviewed
and adjusted to maintain satisfactory hydration, nutrition
status, and growth. Guidelines for nutrition support man-
agement and details of the algorithms for weaning off PS
were provided to the investigators for their consideration
(Supplementary Figure S1). Because of the requirement to
incorporate clinical judgment into decision making, lack
of adherence was not considered a protocol deviation.
Compliance with dosing was monitored by parental re-
ports and study drug accountability by counting used and
unused vials. Data collected at each visit included prede-
fined safety parameters, vital signs, blood samples, urine
and stool output, body weight, body mass index (BMI),
and nutrition support. Height and head circumference (for
patients36months of age) were recorded at selected visits.
Samples for analysis of specific antiteduglutide antibodies
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Figure 1. Study design. After screening, site visits occurred at baseline (day 0) and at the indicated study weeks. For all other
study weeks, patients were contacted by telephone. BL, baseline; SC, subcutaneous; SOC, standard of care.
were collected at baseline, end of treatment (EOT), and end
of study (EOS) visits. Plasma citrulline levels were measured
at baseline, week 12, week 24, and EOS. All data collected
were entered into patient electronic case report forms used
for validation and statistical evaluation. Safety and toler-
ability were evaluated by a Data Monitoring Committee
approximately every 3 months during the treatment period.
The intent-to-treat (ITT) population (all enrolled pa-
tients) and the safety population (all patients who received
SOC or 1 dose of teduglutide and had 1 postbaseline
safety assessment) were identical. Safety end points included
adverse events (AEs), weight, height, head circumference,
BMI z-score, vital signs, chemistry, hematology, and urinal-
ysis. Treatment-emergent AEs (TEAEs; an AE that started
or worsened after the SOC baseline/first dose visit) and
treatment-emergent serious AEs (TESAEs; any medical
occurrence that was judged by the investigator to be an
importantmedical event) were coded using theMedicalDic-
tionary for Regulatory Activities, version 19.1. PS data pre-
sented herein from patient diaries were similar to those from
prescription data. The primary efficacy/pharmacodynamics
(PD) end point, 20% reduction in PS volume at week
24 compared with baseline, was reported as the number
and percentage of patients who achieved this end point.
Other end points included the PS and EN volume and
calories change from baseline at week 24, enteral autonomy
at EOT (ie, no prescribed PS at EOT and no recorded PS
administration for the week before EOT), and the change
from baseline in days per week and hours per day of
PS. Enteral intake data were limited to specialized enteral
formula. PS and EN volume and calories were normalized
to body weight. PD effects on gut mucosa were captured
as the change from baseline in citrulline. All analyses were
performed on the ITT/safety population. Given the rarity
of SBS, the planned sample size was based on the estimated
feasibility of enrollment in the pediatric population with
SBS rather than on power calculations, and no statistical
hypothesis testing of efficacy was therefore prespecified
in the protocol. However, because of unexpectedly high
enrollment, post hoc statistical analysis of the primary end
point and the mean reduction in PS volume was performed.
Limited post hoc statistical comparison on the primary end
point and themost relevant secondary efficacy end point, PS
volume, was performed. Post hoc analysis of the primary
end point between each teduglutide dose group and the
SOC arm, and between each other, employed Fisher exact
test and 95% CI of the difference using the Newcombe-
Wilsonmethodwith continuity correction.Additionally, the
percentage change in PS volume from baseline to EOT was
compared between each teduglutide dose group and the
SOC arm, and between each other, using theWilcoxon rank
sum test. The resulting P-values and CI were not adjusted
for multiplicity. All data values are reported as mean ± SD,
unless otherwise stated.
Deidentified participant data from this study will be
made available. Data requests should follow the process
outlined in the Data Sharing section on Shire’s website
(www.shiretrials.com) and should be directed to clinicaltri-
aldata@shire.com.
Results
Of 59 patients enrolled, 50 patients chose to receive tedug-
lutide and 9 chose to receive SOC; 24 were randomized to
receive 0.025mg/kg and 26 to receive 0.05mg/kg teduglutide
(Figure 2). All patients completed the 24-week treatment
period and 4-week follow-up period. Baseline demographics
and characteristics are summarized in Table 1. The num-
ber of patients receiving EN at baseline was 18 (75%),
25 (96%), and 9 (100%) for the 0.025-mg/kg teduglutide
group, 0.05-mg/kg teduglutide group, and SOC group, re-
spectively. The duration of teduglutide exposure was similar
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Figure 2. CONSORT diagram. Patients in the teduglutide treatment arm received a once-daily subcutaneous injection of
0.025 mg/kg or 0.05 mg/kg teduglutide.
in the 2 dose groups: 169.0 ± 2.69 days in the 0.025-mg/kg
teduglutide group and 167.8 ± 1.33 days in the 0.05-mg/kg
teduglutide group.
Throughout the study, nutrition status remained stable
in all groups. Hydration-related tests showed no clinically
meaningful changes in urine or stool output, urine specific
gravity, blood urea nitrogen, or creatinine (Supplementary
Table S1). The change from baseline at week 24 in height
z-score was –0.09 ± 0.30, 0.04 ± 0.24, and –0.23 ±
0.26 and in BMI z-score was 0.11 ± 0.49, –0.05 ± 0.70,
and 0.37 ± 0.59 for the 0.025-mg/kg teduglutide group,
0.05-mg/kg teduglutide group, and SOC group, respectively
(Supplementary Figure S2).
All patients in the SOC arm and 98% of patients in
the teduglutide dose groups experienced 1 TEAE; none
led to treatment discontinuation. Most patients reported
only mild TEAEs (17%, 0.025 mg/kg teduglutide; 27%,
0.05 mg/kg teduglutide; 44%, SOC) or moderate TEAEs
(63%, 35%, and 56%, respectively). Severe TEAEs (ie, an
intensity level that interrupts usual activities of daily living,
significantly affects clinical status, or may require inten-
sive therapeutic intervention) were reported by 21%, 35%,
and 0%, respectively. The most common TEAEs among
teduglutide-treated patients were pyrexia and vomiting and
in the SOC arm were vomiting, pyrexia, and upper respi-
ratory tract infection (Table 2). Other frequently reported
gastrointestinal-related TEAEs were diarrhea and abdom-
inal pain; overall, gastrointestinal-related TEAEs were
reported by 79%, 77%, and 56% of patients in the
0.025-mg/kg teduglutide group, 0.05-mg/kg teduglutide
group, and SOC group, respectively. Three patients (all in
the 0.025-mg/kg teduglutide dose group) had 3 unrelated
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(n = 26) SOC (n = 9)
Age, years, mean (SD) 7 (4) 6 (4) 6 (5)
Age group, years, n (%)
1–<12 22 (92) 24 (92) 8 (89)
12–<17 2 (8) 2 (8) 0
17–<18 0 0 1 (11)
Sex, n (%)
Male 16 (67) 19 (73) 6 (67)
Race, n (%)
White 16 (67) 21 (81) 2 (22)
Black or African American 3 (13) 3 (11) 1 (11)
Asian 1 (4) 1 (4) 1 (11)
Other 1 (4) 0 2 (22)
Not allowed based on local regulations 3 (13) 1 (4) 3 (33)
Primary reason for SBS diagnosis, n (%)
Necrotizing enterocolitis 5 (21) 3 (12) 2 (22)
Midgut volvulus 10 (42) 6 (23) 3 (33)
Intestinal atresia 2 (8) 1 (4) 0
Gastroschisis 6 (25) 14 (54) 2 (22)
Hirschsprung disease 1 (4) 1 (4) 2 (22)
Other 0 1 (4) 0
Patients with a stoma, n (%) 5 (21) 5 (20) 3 (33)
Type of stomaa
Jejunostomy 3 (60)b 4 (80) 2 (67)
Ileostomy 0 1 (20) 1 (33)
Colostomy 2 (40) 0 0
Total estimated remaining small intestine length, cm, mean (SD) 38 (39) 47 (28) 45 (31)
Patients with remaining colon, n (%) 22 (92) 25 (96) 6 (67)
Estimated percentage of colon remaining, mean (SD) 61 (36) 69 (31) 60 (34)
Colon-in-continuity,c n (%) 22 (100) 22 (88) 6 (100)
Distal/terminal ileum present, n (%) 9 (38) 9 (35) 3 (33)
Ileocecal valve present,d n (%) 6 (67) 7 (78) 3 (100)
Growth parameter at baseline, mean (SD)
Weight z-score –0.9 (1.1) –0.9 (1.1) –0.2 (0.8)
Height z-score –1.3 (1.2) –1.3 (1.2) –0.4 (1.6)
BMI z-score –0.1 (1.1) –0.0 (1.2) 0.1 (0.6)
Head circumference z-scoree –1.8 (0.5) –0.1 (0.5) –1 (N/A)
Patient demographics and baseline disease characteristics were similar in both study arms.
BMI, body mass index; N/A, not available; SBS, short bowel syndrome; SOC, standard of care.
aPercentages are based on the number of patients with a stoma in each treatment group.
bOne patient had a small percentage of colon remaining in continuity, with ileocecal valve.
cPercentages are based on the number of patients who have remaining colon in each treatment group.
dPercentages are based on the number of patients with distal/terminal ileum present in each treatment group.
eFor patients aged 36 months at time of measurement; n = 3 (0.025 mg/kg), n = 4 (0.05 mg/kg), n = 1 (SOC).
TEAEs for hepatobiliary disorders (1 event each of
cholelithiasis, cholestasis, and liver disorder), and 1 patient
in the 0.025-mg/kg teduglutide dose group reported an
unrelated TEAE of increased lipase (>3× upper limit of
normal). In the SOC arm, 1 patient had a TEAE of drug-
induced liver injury due to voriconazole. TEAEs deemed
related to teduglutide treatment by investigators are listed
in Supplementary Table S2. There were 17 types of related
TEAEs in 15 patients; the majority were experienced by a
single patient (injection site bruising, abdominal pain, and
vomiting each occurred in 2 patients). Peripheral edema
occurred in a patient who received 0.025 mg/kg teduglutide.
Fifteen patients (63%) in the 0.025-mg/kg teduglutide dose
group, 20 patients (77%) in the 0.05-mg/kg teduglutide dose
group, and 4 patients (44%) in the SOC arm reported
TESAEs (Supplementary Table S3). Two patients (4%)
treated with teduglutide (both in the 0.025-mg/kg dose
group) experienced TESAEs deemed treatment related by
the investigator: 1 patient was reported to have a fecaloma
that was later clarified by the investigator to be a “hard
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Pyrexia 8 (33) 11 (42) 4 (44)
Vomiting 10 (42) 8 (31) 5 (56)
Cough 2 (8) 10 (39) 3 (33)
Diarrhea 8 (33) 3 (12) 1 (11)
Dehydration 8 (33) 1 (4) 0
Upper respiratory tract
infection
7 (29) 8 (31) 4 (44)
Alanine aminotransferase
increased
7 (29) 2 (8) 0
Nasopharyngitis 4 (17) 6 (23) 2 (22)
Abdominal pain 4 (17) 6 (23) 0
Aspartate aminotransferase
increased
5 (21) 0 0
Headache 3 (13) 5 (19) 1 (11)
Device-related infection 1 (4) 5 (19) 0
Rhinitis 1 (4) 5 (19) 0
Blood bicarbonate
decreased
4 (17) 0 0
Abdominal pain upper 3 (13) 3 (12) 1 (11)
Nausea 3 (13) 3 (12) 1 (11)
Viral infection 3 (13) 3 (12) 1 (11)
Device breakage 3 (13) 3 (12) 0
Conjunctivitis 3 (13) 1 (4) 0
Device occlusion 3 (13) 1 (4) 0
Injection site bruising 3 (13) 1 (4) 0
Rhinorrhea 3 (13) 0 1 (11)
Gastroenteritis viral 3 (13) 0 0
Influenza 2 (8) 3 (12) 0
Ear infection 1 (4) 3 (12) 1 (11)
Catheter site infection 1 (4) 3 (12) 0
Urinary tract infection 2 (8) 1 (4) 1 (11)
Acidosis 2 (8) 1 (4) 0
Blood triglycerides
increased
2 (8) 1 (4) 0
Device dislocation 2 (8) 1 (4) 0
Metabolic acidosis 2 (8) 1 (4) 0
Pain 2 (8) 1 (4) 0
Lymph node palpable 2 (8) 0 1 (11)
Cellulitis 2 (8) 0 0
Gastrointestinal bacterial
overgrowth
2 (8) 0 0
Abdominal pain lower 2 (8) 0 0
Dermatitis diaper 2 (8) 0 0
γ -Glutamyltransferase
increased
2 (8) 0 0
Pain in extremity 2 (8) 0 0
Seasonal allergy 1 (4) 2 (8) 0
Pharyngitis 0 2 (8) 0
Respiratory tract infection 0 2 (8) 0
Stoma site erythema 0 2 (8) 0
Abdominal distension 0 2 (8) 0
AE, adverse event; SOC, standard of care; TEAE,
treatment-emergent adverse event.
Figure 3. Patients achieving the primary study efficacy/PD
end point. Horizontal bars represent the difference in the
percentage of patients achieving a 20% reduction in PS
volume at week 24 for each teduglutide group and SOC group.
PD, pharmacodynamics; PS, parenteral support; SOC,
standard of care.
stool.” Another patient developed an adynamic ileus (no
small bowel obstruction was confirmed). Both events were
serious because of unexpected hospitalization, were mod-
erate in severity, resolved after transient interruption of
teduglutide, and did not recur upon rechallenge. Neither
polyps nor neoplasia were detected during any colonoscopy
or fecal occult blood testing. Therewere noAEs of intestinal
stenosis, congestive heart failure, or AEs attributable to in-
creased absorption of concomitant oral medications. None
of the participants died during the study.
At week 24, 3 patients (13%) treated with 0.025 mg/kg
teduglutide and 5 patients (20%) treated with 0.05 mg/kg
teduglutide had antibodies to teduglutide. Of these 8 pa-
tients, 1 (4%) receiving 0.025 mg/kg teduglutide and 2 (8%)
receiving 0.05 mg/kg teduglutide had neutralizing antibod-
ies present at week 24. At the week-28 follow-up visit,
4 patients (17%) treated with 0.025 mg/kg and 5 patients
(19%) treated with 0.05 mg/kg teduglutide had antibodies
to teduglutide. Of these 9 patients, only 1 (4%) receiving
0.025 mg/kg teduglutide had neutralizing antibodies. The
presence of antiteduglutide antibodies was not associated
with TEAEs of hypersensitivity. All injection site reactions
were mild and nonserious and did not necessitate drug
discontinuation.
The primary efficacy/PD end point, a 20% reduction
in PS volume at week 24, was achieved by 13 patients (54%)
who received 0.025 mg/kg teduglutide, 18 patients (69%)
who received 0.05 mg/kg teduglutide, and 1 patient (11%)
who received SOC (Figure 3). Post hoc analysis evaluated
the statistical differences in response rates between the
0.025-mg/kg group and SOC group of 43.1% (95% CI,
5.5%-63.2%; P = 0.03), between the 0.05-mg/kg and SOC
groups of 58.1% (95% CI, 20.5%-75.1%; P = 0.004), and
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Figure 4. Percentage change from baseline in (A) PS volume and (B) PS calories per patient diary data and z-score change from
baseline in (C) body weight. Error bars represent the standard error. The week 24 vertical dotted line marks the end of the
treatment period and the start of the follow-up period. PS, parenteral support; SEM, standard error of the mean; SOC, standard
of care.
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aBased on prescription data; rounded to nearest whole number.
bBased on the first week when there was no PS prescribed.
between the 0.025-mg/kg group and 0.05-mg/kg group of
15.1% (95% CI, –11.2% to 38.9%; P = 0.21). The absolute
PS volume change at week 24 was –16.2 ± 10.52 mL/kg/d
from a baseline of 56.8 ± 25.24 mL/kg/d in the
0.025-mg/kg teduglutide dose group, –23.3± 17.50mL/kg/d
from a baseline of 60.1 ± 29.19 mL/kg/d in the 0.05-mg/kg
teduglutide dose group, and –6.0 ± 4.55 mL/kg/d from
a baseline of 79.6 ± 31.12 mL/kg/d in the SOC arm;
corresponding percentage changes are illustrated in
Figure 4A. Reductions in PS volume were paralleled by
reductions in PS calories. The absolute PS calories change
at week 24 was –14.9 ± 8.29 kcal/kg/d from a baseline
of 43.3 ± 21.10 kcal/kg/d in the 0.025-mg/kg teduglutide
group, –19.0 ± 14.28 kcal/kg/d from a baseline of 43.3
± 16.52 kcal/kg/d in the 0.05-mg/kg teduglutide dose
group, and −0.5 ± 4.95 kcal/kg/d from a baseline of
44.6 ± 22.53 kcal/kg/d in the SOC arm; corresponding
percentage changes are illustrated in Figure 4B. At week
28, 4 weeks after the treatment period, PS volume and
calories remained substantially reduced compared with
those observed in the SOC arm (Figure 4A and 4B). The
change from baseline in body weight z-score during the
24 weeks of treatment with teduglutide, and the follow-up
period, is illustrated in Figure 4C. The number of days per
week of PS required by patients who received teduglutide
also declined; the change from baseline at week 24 was –0.9
± 1.78 days per week from a baseline of 6.5 ± 1.10 days
per week in the 0.025-mg/kg teduglutide group, –1.3 ±
2.24 days per week from a baseline of 6.6 ± 0.79 days per
week in the 0.05-mg/kg teduglutide dose group, and 0 days
per week from a baseline of 6.6 ± 1.33 days per week in
the SOC arm. The duration of the infusion declined by
–2.5 ± 2.73 hours per day from a baseline of 11.7
± 3.03 hours per day in the 0.025-mg/kg teduglutide
dose group, –3.0 ± 3.84 hours per day from a baseline
of 11.2 ± 2.99 hours per day in the 0.05-mg/kg
teduglutide dose group, and –0.2 ± 0.69 hours per
day from a baseline of 12.6 ± 5.50 hours per day
in the SOC arm. Two patients (8%) who received
0.025 mg/kg teduglutide and 3 patients (12%) who received
0.05 mg/kg teduglutide achieved enteral autonomy. No
patient who received SOC achieved enteral autonomy.
Characteristics of patients who achieved enteral autonomy
are summarized in Table 3. At week 24, the number of
patients receiving EN increased from baseline for the
0.025-mg/kg teduglutide group and 0.05-mg/kg teduglutide
group (23, 96%; 26, 100%, respectively) and remained the
same for the SOC arm (9, 100%). The percentage change in
EN volume from baseline at week 24 was 76.9% ± 117.19%
for the 0.025-mg/kg teduglutide group, 79.5% ± 134.49%
for the 0.05-mg/kg teduglutide group, and –2.5% ± 33.87%
for the SOC arm. The percentage change from baseline
at week 24 in EN calories was 82.7% ± 136.27% for the
0.025-mg/kg teduglutide group, 86.47% ± 128.11% for the
0.05-mg/kg teduglutide group, and 37.1%± 107.53% for the
SOC arm. Plasma citrulline levels increased from baseline to
week 24 during treatment with teduglutide, demonstrating
PD effects on intestinal mass (Supplementary Table S4).
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Discussion
The findings from this 24-week study support the safety,
tolerability, and efficacy/PD of teduglutide in the treatment
of SBS-IF in the pediatric population. This study included
patients with a variety of underlying causes of SBS, remnant
small bowel length, and anatomic configuration, similar to
the epidemiology of the disease in children.20,21 All patients
completed the study, with 80% treatment compliance, and
no patient discontinued the study drug, indicating that daily
treatmentwaswell tolerated. Safety data support findings of
the prior 12-week dosing study of teduglutide in pediatric
patients.5 Most TEAEs considered by a study investigator
to be teduglutide related were single patient events. AEs of
abdominal pain, a known reaction to teduglutide, occurred
more frequently in the teduglutide dose groups than the
SOC arm. The spectrum of TEAEs was similar between
the teduglutide dose groups, and none led to treatment
discontinuation or death. More patients in the teduglutide
dose groups than in the SOC arm reported TESAEs, but
only 2 teduglutide-treated patients experienced a TESAE
considered treatment related by an investigator. In the
previous 12-week pediatric study, no patient developed
neutralizing antibodies to teduglutide.5 During this longer
study, 3 of the 8 patients with antiteduglutide antibodies at
week 24 developed neutralizing antibodies, but antibodies
were not associated with lack of efficacy or with TEAEs of
hypersensitivity. None of the mild, nonserious injection site
reactions resulted in drug discontinuation.
Significantly more patients with SBS-IF treated with
teduglutide than those on SOC achieved the primary end
point of a 20% reduction in PS volume at week 24:
54% and 69% (0.025 mg/kg and 0.05 mg/kg teduglutide,
respectively) vs 11% (SOC; differences with teduglutide
dose groups, P < 0.05 for both). Teduglutide treatment
resulted in clinically meaningful reductions in PS in pedi-
atric patients over 24 weeks of treatment using diary and
prescription data (not shown). From baseline to week 24,
the mean percentage changes in PS volume were −36%
and –42% in the 0.025-mg/kg teduglutide group and
0.05-mg/kg teduglutide dose groups, respectively, and –10%
in the SOCarm.Reductions in PS volume and calories in the
2 teduglutide dose groups were associated with substantial
increases in EN volume and calories. Limiting EN data to
specialized formula missed potential improvements in other
oral intake. No clinically meaningful changes in weight,
height, BMI z-scores, and urine or stool output occurred,
indicating that the reductions in PS in the teduglutide-
treated patients did not compromise the patients’ nutrition
status. For the patients treated with 0.05 mg/kg teduglutide,
PS infusions were reduced by an average of 1.3 days per
week. Treatment with teduglutide was associated with in-
creased plasma citrulline level consistent with a teduglutide-
induced increase in intestinal epithelial mass. Four weeks
after discontinuation of treatment, citrulline levels declined
to near baseline levels, suggesting that continued treatment
with teduglutide is necessary to maintain the trophic effect
on the gut epithelium. The slight reduction in PS and
increase in EN observed in the SOC arm during the study
may reflect spontaneous adaptation or improved medical
management without pharmacologic intervention. Unlike
patients who received SOC, 2 patients from the 0.025-mg/kg
teduglutide group and 3 from the 0.05-mg/kg teduglutide
dose group achieved enteral autonomy by week 24. Of these
5 patients, 1 had an intact terminal ileum and ileocecal
valve, 4 had colon-in-continuity, and 2 had remnant bowel
length of 120 cm. Both teduglutide dose groups showed
PS reductions similar to those observed in the previous 12-
week study, suggesting that the majority of the PD effects
occurred within 12 weeks. However, 3 of the 5 patients
who achieved enteral autonomy did so only after 12 weeks
of treatment. A long-term study is needed to determine
whether further reductions in PS occur with additional
teduglutide treatment and whether reductions in PS can be
sustained if teduglutide treatment is discontinued. In this
double-blind study comparing 0.025-mg/kg and 0.05-mg/kg
doses, the 0.05-mg/kg teduglutide dose group showed a
numerically greater effect in all efficacy and PD parameters,
including responder rate; mean reductions in PS volume,
calories, and infusion days per week; and higher plasma
citrulline. These small differences, as illustrated in Figure 4,
suggest that the dose-response relationship in children is
relatively flat within this dose range and that doses above
0.05 mg/kg/d are unlikely to provide greater benefit.
Limitations of this study include open-label treatment
allocation and ability to choose teduglutide vs SOC treat-
ment, allowing selection and reporting bias. It is possible
that patients with less frequent or severe complications
of SBS at baseline may have chosen SOC rather than
teduglutide. Selection bias may also account for the higher
baseline weight and height z-scores in the SOC arm.
The nonblinded SOC arm also makes the safety data for
teduglutide vulnerable to reporting bias for AEs. Although
investigators were to apply the same nutrition support
adjustment algorithm to all patients, the nonblinded SOC
arm coupled with expected clinical benefit from teduglutide
may have biased PS adjustments. Future analyses from the
ongoing extension studies (NCT02949362/EudraCT2016-
000862-17, NCT02954458/EudraCT2016-000849-30) may
identify characteristics predicting responsiveness to tedug-
lutide in children with SBS-IF. Identifications of such
factors may inform patient selection, which may be relevant
for assessment of the cost-effectiveness of tedulglutide.
In this study, the safety profile was similar in both dosing
groups and consistent with previous experience in adults
and children with SBS-IF.5,13,14 In conjunction with expert
management by intestinal rehabilitation specialists in this
study, daily injection of teduglutide was well tolerated and
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promoted intestinal adaptation, as evidenced by reductions
of PS requirements in children with SBS-IF. The post hoc
statistical analysis of the primary efficacy end point and
change in mean PS volume supports the clinically mean-
ingful improvements observed in the teduglutide groups
(P < 0.05 vs SOC). PS reductions in response to treatment
with teduglutide are expected to reduce the long-term risks
associated with PS and may also improve quality of life of
children with SBS-IF.7,8,22
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